Biotech ETFs Pop on Celgene, Juno Deal

Biotechnology sector-related ETFs surged Monday after Celgene (NasdaqGS: CELG) said it will acquire Juno Therapeutics (NasdaqGS: JUNO) to expand its cancer treatment profile.

Among the best performing biotech-related ETFs, the First Trust NYSE Arca Biotechnology Index Fund (NYSEArca: FBT) jumped 5.5% and the SPDR S&P Biotech ETF (NYSEArca: XBI) increased 4.9% while the iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), the largest biotech-related ETF, gained 2.9%.

Meanwhile, CELG was up 0.1% and JUNO increased 26.6%.

FBT has 3.3% JUNO and 3.3% CELG. XBI includes 1.7% JUNO and 1.4% CELG. IBB holds 7.7% CELG and 1.0% JUNO.

For the more aggressive traders, the Direxion Daily S&P Biotech Bull Shares (NYSEArca: LABU), which takes the 3x or 300% daily performance of the S&P Biotechnology Select Industry Index, advanced 14.6% and the ProShares UltraPro Nasdaq Biotechnology (NasdaqGM: UBIO), which takes the 3x daily performance of the Nasdaq Biotechnology Index, surged 8.4%.

Biotech stocks strengthened after Celgene announced it will acquire Juno Therapeutics for $87 per share in cash or about $9 billion, reports Cara Lombardo for the Wall Street Journal. The WSJ reported last week that the two firms were already working on a deal.